HUMIRA is a medicine called a Tumor Necrosis Factor (TNF) blocker.
HUMIRA is used to reduce the signs and symptoms of:
The recommended subcutaneous dosage of HUMIRA for adult patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) is 40 mg administered every other week. Methotrexate (MTX), other non-biologic DMARDS, glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be continued during treatment with HUMIRA. In the treatment of RA, some patients not taking concomitant MTX may derive additional benefit from increasing the dosage of HUMIRA to 40 mg every week or 80 mg every other week.
The most common side effects include:
There are several programs patients can sign up for that will assist in treatment costs:
To learn more about this treatment, browse the resources below.
Contact us to chat with one of our helpful scheduling specialists!